Drug intelligence / Profile preview

NTX3A13

Development stage: Preclinical
Lead developer: Nectin Therapeutics
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NTX3A13 is a first-in-class multispecific therapeutic antibody being developed by Nectin Therapeutics for the treatment of cancer. It is engineered to simultaneously recognize and bind to multiple antigens, including a key member of the nectin pathway. By integrating multiple high-affinity binding capabilities, NTX3A13 aims to target cancer cells more effectively and overcome resistance mechanisms associated with current therapies. The drug is currently in the lead-selection stage of preclinical development, leveraging Nectin Therapeutics' expertise in the nectin pathway to create next-generation immuno-oncology therapies.

Targets

PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on NTX3A13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX3A13.

Explore the full profile